Celldex: Update Based on 2Q, 2016 Conference Call (CLDX, Neutral, $4.45)Investment View Celldex has a broad array of clinical trials underway or in planning that involve five drugs. However, most of… Celldex: ACT IV Trial of Rintega in Newly Diagnosed Glioblastoma has Been Terminated (CLDX, Hold, $4.01)ACT-IV Trial is Halted The independent Data Safety and Monitoring Board (DSMB) just completed its second interim review of the phase… Celldex: Meaningful Data on Two Lead Products, Rintega and glembatumumab, is not Likely Before 2017 (CLDX, Hold, $16.99)Key Points; The big news of the 2Q, 2015 conference call was that the FDA has discouraged Celldex from filing an… Comments on Agenus, Neuralstem and CelldexSmithOnStocks Mailbox Celldex Pipeline Update and Investment Thesis (CLDX, Moving from Buy to Hold, $28.56)Overview SmithOnStocks Mailbox, January 31 Edition: My Take on News Events Relating to Companies I FollowIntroduction A number of subscribers have suggested that I write more on recent news events that relate to companies that I… Immuno-Oncology Promises to be the Next “Big Thing” In BiotechnologyImmuno-Oncology Promises to be the Next “Big Thing” In Biotechnology Immuno-oncology has been the hottest area in biotechnology… Celldex, Moving to A Buy (CLDX, $14.16)Investment Thesis Celldex held a conference call after the close on Friday, November 14, 2014 to discuss the interim results of… Thoughts on the Market Correction in Biotechnology StocksThis Has Been a Tough Correction The recent sharp market correction and rotation out of growth stocks like biotechnology and technology… Celldex: I View the Recent Data on Rindopepimut as Encouraging (CLDX, Hold, $22.52) (Subscribers Only)Report Overview Celldex: Equity Offering is a Positive for the Stock (CLDX, Hold, $25.88)Celldex (CLDX) has just announced a financing in which the Company has issued 7.0 million shares and will receive net… Celldex Stay Tuned for Monday’s Conference Call on Rindopepimut (CLDX, Hold, $28.31)Investment Significance of Upcoming Conference Call Celldex (CLDX, $23.06): Previewing the Imminent Data Release on RindopepimutNote: Comprehensive reports are now available to paid subscribers and can be found in the Reports section. Investment Background and Thesis Celldex (CLDX, $23.06): Previewing the Imminent Data Release on RindopepimutInvestment Background and Thesis Celldex: Why Investors Are So Excited About the Company (CLDX, Hold, $24.39)This post is an excerpt from the report: Celldex: Pipeline Promise Has Been Embraced by Wall Street Comprehensive reports are now available… Celldex Initiation Report: Pipeline Promise Has Been Embraced by Wall Street (CLDX, Hold, $22.79)Review of Amazing and Volatile Stock Price Performance |